Table 1 Model parameters
From: Economic impact of a more extensive use of FENO testing on the Italian population with asthma
Description | Value | Reference |
|---|---|---|
Clinical parameters | ||
Relative risk reduction of hospitalization for serious exacerbation | 83% | Green 2002 [19] |
Relative risk reduction of non-serious exacerbations | 29% | Jayaram 2006 [20] |
Reduction in ICS dose | 42% | Smith 2005 [21] |
Rates of adverse events by short term use of oral corticosteroids (per person year at risk) | ||
Sepsis | 0.0018 | Waljee 2017 [25] |
Venous thromboembolism | 0.0046 | Waljee 2017 [25] |
Fractures | 0.0214 | Waljee 2017 [25] |
Healthcare resource use | ||
Period between two follow-up visits for standard of care strategy (months) | 6.00 | GINA guidelines [7] |
Period between two follow-up visits for FeNO strategy (months) | 6.00 | GINA guidelines [7] |
Costs | ||
Asthma visit | 16.20€ | National tariff 89.01.L |
FENO test | 23.20€ | National tariff 93.99.4 |
Spirometry | 24.00€ | National tariff 89.37.1 |
Severe asthma exacerbation | 2,537€ | DRG 096 (age > 17 years, with complications) |
1,832€ | DRG 097 (age > 17 years, without complications) | |
1,538€ | DRG 098 (age < 18 years) | |
Non-severe asthma exacerbation | 330€ | Pugliese 2020 [26] |
Sepsis | 29,985.08€ | Lucioni 2001 [29] |
Venous thromboembolism | 1,570.24€ | Gussoni 2013 [27] |
Fractures | 6,311.40€ | Degli Esposti 2011 [28] |
ICS and associations for asthma (total cost for Italy) | 663,200,000€ | OSMED 2018 [30] |
Other drugs for asthma (total cost for Italy) | 317,500,000€ | OSMED 2018 [30] |